A new clinical trial for people with advanced pancreatic cancer, has now commenced in Australia. The trial led by Amplia Therapeutics, in collaboration with Professor Paul Timpson from the Invasion and Metastasis Lab at The Garvan Institute of Medical Research, will...

Pancreatic cancer is one of the most aggressive cancers and five-year survival rates are just 10%. A very small number of patients live longer, with less than 2% surviving more than 10 years after diagnosis. Researchers have been working to understand how this cancer...

The Avner Australian Pancreatic Cancer Matrix Atlas group (APMA) will investigate a potential new way to improve immunotherapy outcomes for patients with pancreatic cancer using a class of drug that can reduce the metabolic rewiring of the cancer cells thanks to a...